financetom
Business
financetom
/
Business
/
Olaplex Q3 Adjusted EPS, Sales Decrease; 2024 Sales Outlook Lowered -- Shares Fall
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Olaplex Q3 Adjusted EPS, Sales Decrease; 2024 Sales Outlook Lowered -- Shares Fall
Nov 9, 2024 12:18 PM

10:20 AM EST, 11/07/2024 (MT Newswires) -- Olaplex ( OLPX ) shares were falling past 17% in recent Thursday trading after the company reported lower Q3 adjusted earnings and net sales and cut its fiscal 2024 net sales guidance.

The company reported Q3 adjusted earnings Thursday of $0.04 per diluted share, down from $0.05 a year earlier.

Analysts polled by Capital IQ expected $0.04.

Net sales for the quarter ended Sept. 30 were $119.1 million, down from $123.6 million a year earlier.

Analysts surveyed by Capital IQ expected $126.5 million.

The company said it now expects fiscal 2024 net sales between $405 million and $415 million, down from its previous guidance between $435 million and $463 million.

Analysts polled by Capital IQ expect $447.4 million.

Price: 1.47, Change: -0.33, Percent Change: -18.16

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sight Sciences Says Omni Surgical System Gains UnitedHealthcare Coverage
Sight Sciences Says Omni Surgical System Gains UnitedHealthcare Coverage
Sep 9, 2025
07:57 AM EDT, 09/09/2025 (MT Newswires) -- Sight Sciences ( SGHT ) said Tuesday its Omni system will be included in UnitedHealthcare's expanded coverage of glaucoma surgical treatments starting Oct. 1. The update applies to commercial and individual exchange benefit plans covering about 30 million members, the company said. UnitedHealth's ( UNH ) UnitedHealthcare will cover goniotomy, trabeculotomy, canaloplasty, and...
Regeneron Says 5-Year Data Show Libtayo Improved Survival Outcomes in Lung Cancer
Regeneron Says 5-Year Data Show Libtayo Improved Survival Outcomes in Lung Cancer
Sep 9, 2025
07:57 AM EDT, 09/09/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Tuesday that five-year follow-up data on its phase 3 trial for Libtayo show the treatment produced a significant improvement in survival outcomes in adults with non-small cell lung cancer. The data showed that Libtayo plus platinum-based chemotherapy demonstrated a overall survival rate of 19.4% compared to 8.8%...
Top Premarket Decliners
Top Premarket Decliners
Sep 9, 2025
07:58 AM EDT, 09/09/2025 (MT Newswires) -- AlphaVest Acquisition ( ATMV ) shares were 23% lower pre-bell Tuesday, paring Monday's rally. Senmiao Technology ( AIHS ) stock was down 17%, reversing from Monday's increase. PACS Group ( PACS ) shares were 15% lower, a day after the company said that Chief Financial Officer Derick Apt resigned after an investigation found...
Unilever's Magnum Targets 3%-5% Average Annual Organic Sales Growth Post Spin-Off
Unilever's Magnum Targets 3%-5% Average Annual Organic Sales Growth Post Spin-Off
Sep 9, 2025
07:57 AM EDT, 09/09/2025 (MT Newswires) -- Unilever ( UL ) unit Magnum Ice Cream Co. is targeting average annual organic sales growth of 3%-5% in the medium term from 2026 when it is spun off from the parent firm, it said Tuesday. Ahead of its first meeting with investors, the company said its expects an improvement in its average...
Copyright 2023-2026 - www.financetom.com All Rights Reserved